🇺🇸 FDA
Patent

US 11571440

Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion

granted A61KA61K2039/5156A61K2039/5158

Quick answer

US patent 11571440 (Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion) held by Jazz Pharmaceuticals Ireland Limited expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jazz Pharmaceuticals Ireland Limited
Grant date
Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/5156, A61K2039/5158, A61K31/711, A61K39/0011